Universal-Beteiligungs- und Servicegesellschaft
SMMT icon

Universal-Beteiligungs- und Servicegesellschaft’s Summit Therapeutics SMMT Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,670
Closed -$291K – 2155
2025
Q2 		$291K Sell
13,670
-2,310
-14% -$52.7K ﹤0.01% 1838
2025
Q1 		$308K Buy
+15,980
New +$321K ﹤0.01% 1778

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's SMMT Position: Q3 2025 in Review

Universal-Beteiligungs- und Servicegesellschaft sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 13,670 shares — an estimated $291K sold.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in SMMT in Q1 2025 and held it in 2 quarters. The position peaked at $308K in Q1 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Universal-Beteiligungs- und Servicegesellschaft reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Universal-Beteiligungs- und Servicegesellschaft sold 13,670 Summit Therapeutics shares in Q3 2025, an estimated $291K.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in Summit Therapeutics in Q1 2025 and held it in 2 quarters.
  • Universal-Beteiligungs- und Servicegesellschaft's Summit Therapeutics position peaked at $308K in Q1 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q3 2025, filed 30 Oct 2025.